Alzinova’s drug candidate ALZ‑101 has previously completed a Phase 1b study that met the primary and secondary endpoints for safety, tolerability and immunogenicity.
The company is now working, together with its selected CRO Worldwide Clinical Trials, on preparations for the Phase II study, including regulatory and ethical submissions and the allocation of trial sites.
BREAKING